MedTrace Logo

Awareness of Prediabetes Among Physicians

NCT07650513 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-06-16

No results posted yet for this study

Summary

Prediabetes is associated with impaired fasting glucose and/or impaired glucose tolerance. Recent data indicate that more than one-third of adults in affluent countries have prediabetes . Fasting glucose concentrations of 100-125 mg/dL, hemoglobin A1c (HbA1c) titers of 5.7-6.4%, and two-hour post-stimulus glucose levels of 140-199 mg/dL are used to identify prediabetes. Behavioral lifestyle changes and medications are useful in preventing the progression of prediabetes to T2DM .

Early detection and treatment of T2DM and prediabetes can prevent future health problems. However, many people with metabolic disorders are undiagnosed, partly due to the clinical practices and knowledge of primary care physicians (PCPs). PCPs play a critical role in diabetes prevention through the detection and management of prediabetes. Successful screening initiatives and the start of appropriate management interventions depend on PCPs' level of prediabetes knowledge Most patients with prediabetes do not receive evidence-based preventive care from their PCPs . Systemic barriers hinder physicians' ability to provide the best evidence-based practice, such as performance measures, insurance reimbursement, cultural expectations, and a lack of tools and staffing resources

Conditions

  • Pre Diabetes
  • Awarness of Physcian About Prediabetes

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07650513 on ClinicalTrials.gov